BioCentury
ARTICLE | Company News

Emergent BioSolutions, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services infectious news

October 10, 2016 7:00 AM UTC

HHS’s Biomedical Advanced Research and Development Authority (BARDA) granted Emergent a contract worth up to $1.6 billion to develop NuThrax ( AV7909). Emergent said the contract includes about $200 million over five years to develop the vaccine and to supply an initial 2 million doses for the U.S. Strategic National Stockpile. NuThrax is in Phase III testing, and Emergent said it believes FDA could approve the vaccine for emergency use as soon as 2018. The contract also includes up to $1.4 billion for the supply of up to 50 million doses of NuThrax to the national stockpile. NuThrax is a third-generation vaccine consisting of BioThrax, an adsorbed anthrax vaccine, plus an immunostimulatory compound called CPG 7909 for postexposure prophylaxis of anthrax disease. ...